Cargando…

Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with (64)Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts

Peritoneal dissemination is a common cause of death from gastrointestinal cancers and is difficult to treat using current therapeutic options, particularly late-phase disease. Here, we investigated the feasibility of integrated therapy using (64)Cu-intraperitoneal radioimmunotherapy (ipRIT), alone o...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshii, Yukie, Yoshimoto, Mitsuyoshi, Matsumoto, Hiroki, Tashima, Hideaki, Iwao, Yuma, Takuwa, Hiroyuki, Yoshida, Eiji, Wakizaka, Hidekatsu, Yamaya, Taiga, Zhang, Ming-Rong, Sugyo, Aya, Hanadate, Sayaka, Tsuji, Atsushi B., Higashi, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034757/
https://www.ncbi.nlm.nih.gov/pubmed/29989003
http://dx.doi.org/10.18632/oncotarget.25649
_version_ 1783337930482253824
author Yoshii, Yukie
Yoshimoto, Mitsuyoshi
Matsumoto, Hiroki
Tashima, Hideaki
Iwao, Yuma
Takuwa, Hiroyuki
Yoshida, Eiji
Wakizaka, Hidekatsu
Yamaya, Taiga
Zhang, Ming-Rong
Sugyo, Aya
Hanadate, Sayaka
Tsuji, Atsushi B.
Higashi, Tatsuya
author_facet Yoshii, Yukie
Yoshimoto, Mitsuyoshi
Matsumoto, Hiroki
Tashima, Hideaki
Iwao, Yuma
Takuwa, Hiroyuki
Yoshida, Eiji
Wakizaka, Hidekatsu
Yamaya, Taiga
Zhang, Ming-Rong
Sugyo, Aya
Hanadate, Sayaka
Tsuji, Atsushi B.
Higashi, Tatsuya
author_sort Yoshii, Yukie
collection PubMed
description Peritoneal dissemination is a common cause of death from gastrointestinal cancers and is difficult to treat using current therapeutic options, particularly late-phase disease. Here, we investigated the feasibility of integrated therapy using (64)Cu-intraperitoneal radioimmunotherapy (ipRIT), alone or in combination with positron emission tomography (PET)-guided surgery using a theranostic agent ((64)Cu-labeled anti-epidermal growth factor receptor antibody cetuximab) to treat early- and late-phase peritoneal dissemination in mouse models. In this study, we utilized the OpenPET system, which has open space for conducting surgery while monitoring objects at high resolution in real time, as a novel approach to make PET-guided surgery feasible. (64)Cu-ipRIT with cetuximab inhibited tumor growth and prolonged survival with little toxicity in mice with early-phase peritoneal dissemination of small lesions. For late-phase peritoneal dissemination, a combination of (64)Cu-ipRIT for down-staging and subsequent OpenPET-guided surgery for resecting large tumor masses effectively prolonged survival. OpenPET clearly detected tumors (≥3 mm in size) behind other organs in the peritoneal cavity and was useful for confirming the presence or absence of residual tumors during an operation. These findings suggest that integrated (64)Cu therapy can serve as a novel treatment strategy for peritoneal dissemination.
format Online
Article
Text
id pubmed-6034757
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-60347572018-07-09 Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with (64)Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts Yoshii, Yukie Yoshimoto, Mitsuyoshi Matsumoto, Hiroki Tashima, Hideaki Iwao, Yuma Takuwa, Hiroyuki Yoshida, Eiji Wakizaka, Hidekatsu Yamaya, Taiga Zhang, Ming-Rong Sugyo, Aya Hanadate, Sayaka Tsuji, Atsushi B. Higashi, Tatsuya Oncotarget Research Paper Peritoneal dissemination is a common cause of death from gastrointestinal cancers and is difficult to treat using current therapeutic options, particularly late-phase disease. Here, we investigated the feasibility of integrated therapy using (64)Cu-intraperitoneal radioimmunotherapy (ipRIT), alone or in combination with positron emission tomography (PET)-guided surgery using a theranostic agent ((64)Cu-labeled anti-epidermal growth factor receptor antibody cetuximab) to treat early- and late-phase peritoneal dissemination in mouse models. In this study, we utilized the OpenPET system, which has open space for conducting surgery while monitoring objects at high resolution in real time, as a novel approach to make PET-guided surgery feasible. (64)Cu-ipRIT with cetuximab inhibited tumor growth and prolonged survival with little toxicity in mice with early-phase peritoneal dissemination of small lesions. For late-phase peritoneal dissemination, a combination of (64)Cu-ipRIT for down-staging and subsequent OpenPET-guided surgery for resecting large tumor masses effectively prolonged survival. OpenPET clearly detected tumors (≥3 mm in size) behind other organs in the peritoneal cavity and was useful for confirming the presence or absence of residual tumors during an operation. These findings suggest that integrated (64)Cu therapy can serve as a novel treatment strategy for peritoneal dissemination. Impact Journals LLC 2018-06-22 /pmc/articles/PMC6034757/ /pubmed/29989003 http://dx.doi.org/10.18632/oncotarget.25649 Text en Copyright: © 2018 Yoshii et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Yoshii, Yukie
Yoshimoto, Mitsuyoshi
Matsumoto, Hiroki
Tashima, Hideaki
Iwao, Yuma
Takuwa, Hiroyuki
Yoshida, Eiji
Wakizaka, Hidekatsu
Yamaya, Taiga
Zhang, Ming-Rong
Sugyo, Aya
Hanadate, Sayaka
Tsuji, Atsushi B.
Higashi, Tatsuya
Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with (64)Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts
title Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with (64)Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts
title_full Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with (64)Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts
title_fullStr Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with (64)Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts
title_full_unstemmed Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with (64)Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts
title_short Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with (64)Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts
title_sort integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with (64)cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034757/
https://www.ncbi.nlm.nih.gov/pubmed/29989003
http://dx.doi.org/10.18632/oncotarget.25649
work_keys_str_mv AT yoshiiyukie integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts
AT yoshimotomitsuyoshi integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts
AT matsumotohiroki integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts
AT tashimahideaki integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts
AT iwaoyuma integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts
AT takuwahiroyuki integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts
AT yoshidaeiji integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts
AT wakizakahidekatsu integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts
AT yamayataiga integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts
AT zhangmingrong integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts
AT sugyoaya integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts
AT hanadatesayaka integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts
AT tsujiatsushib integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts
AT higashitatsuya integratedtreatmentusingintraperitonealradioimmunotherapyandpositronemissiontomographyguidedsurgerywith64culabeledcetuximabtotreatearlyandlatephaseperitonealdisseminationinhumangastrointestinalcancerxenografts